Role Of Clinical Pharmacologist Research Articles

Mucormycosis and role of clinical pharmacologist

Mucormycosis (zygomycosis) is a fungal infection (serious but rare) caused by a group of molds called mucoromycetes and it is considered the third most common invasive fungal disease after candidiasis and aspergillosis (1) infection occurs by coming in contact with the fungal spores in the environment. There are several types such as Rhino cerebral (sinus and brain) Mucormycosis, Pulmonary (lung) mucormycosis, Gastrointestinal mucormycosis, Cutaneous (skin) Mucormycosis, Disseminated Mucormycosis. Diagnosis is done on the basis of biopsy, histological examination, CT scan or MRI. With the help of Early diagnosis, Early administration of active antifungal agents, Reversal of underlying factor Complete removal of all infected tissues, use of various adjunctive therapies we can treat Mucormycosis. In the era of Covid due to exposure of various immunosuppressant’s Mucormycosis cases are hiked, and due to this there is key role of clinical pharmacologist to maintain drug therapy with accurate drug dosing regimen and correlate the drug therapy with other possible risk factors. This review aims the detailed clinical information of Mucormycosis and Role of Clinical Pharmacologist in the management of Mucormycosis.

Mucormycosis and role of clinical pharmacologist

Mucormycosis and role of clinical pharmacologist

The importance of a professional standard in clinical pharmacologist’s work in a medical organization

The article describes the main functions of a clinical pharmacologist in medico-preventive institution according to the draft “Professional standart “clinical pharmacologist”. The role of clinical pharmacologist and its importance in the work of medical organization according to the orders of Ministry of Health (No 131 of May 05, 1997; No 494 of October 22, 2003; No 575н of November 02, 2012).

P1.3 - Pregnancy Exposure to Drugs: Role of Clinical Pharmacologist

P1.3 - Pregnancy Exposure to Drugs: Role of Clinical Pharmacologist

English

English

An agenda for UK clinical pharmacology: The roles of clinical pharmacologists in UK universities

Clinical pharmacologists in universities play major roles in research and teaching and provide important contributions to National Health Service (NHS) activities, such as work for research ethics, drug and therapeutics, and clinical governance committees. Their research extends from preclinical studies using drugs to understand physiology and the mechanisms of disease to large‐scale clinical trials and population studies. This work is truly translational, with a focus on drugs and medicines and an emphasis on efficacy and safety. The lack of an organ base has allowed clinical pharmacologists to follow their interests wherever they lead, but their visibility has been hampered by successive earlier versions of the General Medical Council's Tomorrow's Doctors document, which undermined some of the necessary scientific underpinning of medical practice and reduced the time clinical pharmacologists had to interact with medical students and recently qualified doctors at the point of choosing their careers. Additional problems have arisen from the stifling effect of the European Union Clinical Trials Directive, and its UK interpretation, on clinical research. For future success, clinical pharmacologists need to embrace translational research, use recent changes to Tomorrow's Doctors, linked to the creation of safe prescribing skills, to spend more face‐to‐face time with their students, fight for a simplification and proportionate regulation of research, and persuade doctors, health service planners and the government of the importance of clinical pharmacology for UK clinical research, the NHS, patient safety and creation of health and wealth.

An agenda for UK clinical pharmacology: UK medicines policy: the role of clinical pharmacologists

Clinical pharmacologists are the only medical specialists whose training focuses specifically on the safe, effective and cost‐effective use of medicines, underpinned by an understanding of drug discovery, drug regulation, pharmacology, translational medicine and the performance of clinical trials. This unique perspective has allowed them to provide expertise and leadership in medicines regulation, medicines policy, health technology assessment and drug pricing. Clinical pharmacologists assisted in the creation of the Committee on Safety of Medicines (now the Commission on Human Medicines), the Yellow Card Scheme, the National Institute of Health and Clinical Excellence (NICE) and related organizations in Scotland and Wales, and contributed to clinical guidelines (through the Scottish Intercollegiate Guidelines Network) and the British National Formulary. Their research work has contributed substantially, through translational medicine and therapeutics, to the development of new medicines and, as a result, creation of health and wealth in the UK. Their work in medicines policy has served to protect patients from harms associated with the use of medicines. A reduction in the number of able junior doctors attracted to a career in clinical pharmacology, a reduction in the number of training posts, and an ageing population of academic trainers, puts the future of the specialty, and its contribution to patient safety and UK wealth creation, at substantial risk. Urgent measures are needed to convince the NHS and government that these essential skills should be protected and nurtured.

An agenda for UK clinical pharmacology: The roles of clinical pharmacologists in formulating medicines policy locally

Specialists in Clinical Pharmacology and Therapeutics (CPT) can add value in day-to-day NHS activities in several ways. They provide a breadth of expertise that is not organ-based or disease-specific and that is based on an intimate knowledge and understanding of the effectiveness, safety and cost-effectiveness of pharmacological interventions. More than any other professional group, they can address the growing need for undergraduate and postgraduate teaching to be based on 'thoughtful therapeutics', not just the mechanics of prescribing. CPT specialists can and do take the lead in making local and national policy decisions relating to drug usage and they should be involved in local commissioning decisions. Because of the breadth of experience embraced by CPT, many clinical pharmacologists have taken on local and national senior clinical leadership roles. CPT needs to demonstrate to the NHS, and in particular to trainees, that a CPT post in the NHS is a legitimate and rewarding career path, where they can use their hard earned CPT skills and expertise to the benefit of the NHS as a whole.

The role of the paediatric clinical pharmacologist in paediatric research

In 1970 the World Health Organization stated that the function of the clinical pharmacologist was: 1) to improve patient care by promoting safer and more effective use of drugs, 2) to increase knowledge through research, 3) to pass on knowledge through teaching and 4) to provide services (e.g., analyses, drug information, and advice in the design of experiments). The role of the clinical pharmacologist in the fields of drug discovery, drug development, and regulatory sciences has significantly changed over the last decades. There is no discussion about the pivotal role of clinical pharmacologists in ensuring rational use of drugs, in translating pharmacological concepts from the bench to the clinic, in clinical drug development, or in teaching the discipline to medical and pharmacy students. Specifically, the role of paediatric clinical pharmacology is evolving and changing dramatically. This paper will summarize the current role of the (paediatric) clinical pharmacologist.

Clinical Pharmacology: Opportunities for Educating New Practitioners—An Australian Perspective

There has been a transformation in the role of clinical pharmacologists in Australasia. The traditional approach was for medically qualified, college-accredited (postgraduate education), hospital-based clinical pharmacologists to confine themselves mainly to a local focus. Today many more opportunities exist for expanding the roles of health professionals who have the clinical pharmacology training. These professionals can influence national and international policy, practice, and education in their field. However, the new roles do require extra initiatives in providing educational input in clinical pharmacology to take care of future needs. Some of the potential gaps in the process are identified in this article.

THE EFFECT OF THE NEW F.D.A. REGULATIONS ON THE DRUG INDUSTRY.

Since the proposed regulations regarding clinical investigation of new drugs were published in the Federal Register, the pharmaceutical industry, the clinical investigator, the Food and Drug Administration itself have been plunged into a tremendously disruptive and costly activity. The Food and Drug Administration may not have realized all the problems that the new regulatioru have created. However, without their gUidance on policy and a mutual sense of trust and helpfulness, the industry cannot effectively approach some of the problems relating to the delineation of authority and responsibility of clinical investigators, the role of clinical pharmacologists in the initial assessment of new drugs, the basis for assessment of utility of numerous prescription drugs cleared by the F.D.A. on the basis of safety prior to Oct. 10, 1962, and the reporting and collation of adverse reactioru. Wisely and efficiently administered, the new regulations can go a long way toward raising the standards of drug research, but it is clear that the pharmaceutical companies will be called on for still greater total research capability and expenditures if we are to maintain, in this new environment, the tremendous strides that have been made in the advancements of therapy in our generation.